Mass Spectrometry-Based Proteomics Study on Candida Infection of COVID-19 Patients to Discover New Antifungal Target

Abstract

The molecular foundation of fungal disease can now be better understood and treated because to advances in mass spectrometry (MS) based proteomics technology. Numerous disease-related biomarkers and potential new drug targets have been discovered over the course of the past 30 years of proteomics research, which examines dynamic protein expression, post-translational modifications, cellular and sub-cellular protein distribution, and protein–protein interactions. Although MS proteomics was of paramount importance to understanding the molecular progression involved in their differential expressions but was challenging under invasive and non-invasive growth conditions of Candida. species but was challenging especially due to the lack of diagnostic morphological features for early prediction. The long-term goal of this chapter is to identify the biomarkers relevant for early prediction and future target molecules for drug discovery and to determine proteins linked to fungal action, made the identification of alterations in fungal physiology and host-pathogen interactions between cells and antibiotics during COVID-19 infection therapy. Here, we also discussed the developments of proteomic-driven interactions between the host and the fungal pathogens, clinical application of spectrometry-based Candida. proteome identification diagnosis, and treatment with antibiotics. Proteomic approach advancements open new pathways for effective prevention and medication development for infectious diseases brought on by fungi.